| 自营销售 | 388 | 310 | 20.10 | 434 | 338 | 22.12 | | --- | --- | --- | --- | --- | --- | --- | | 联营销售 | 187 | 10 | 94.65 | 191 | 39 | 79.58 | 自营销售 12,184 6,766 44.47 12,819 7,526 41.29 医药销售 上海新世界股份有限公司2025 年半年度报告 公司代码：600628 公司简称：新世界 上海新世界股份有限公司 上海新世界股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不存在虚假记 载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人董事长陈湧先生，副董事长、总经理沈为民先生、主管会计工作负责人财务总监余长炜先 生及会计机构负责人（会计主管人员）财务部经理戎艳女士声明：保证半年度报告中财务报告的真实、准确、 完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预 ...

【来源：运城市场监管】 调研组要求 要强化源头治理，前置化解消费纠纷。消费维权服务站应成为沟通消费者与经营主体的第一道桥梁，充 分发挥其"前哨"作用，严格落实消费纠纷前端化、源头化化解要求，建立健全消费纠纷自我调处机制， 定期分析投诉热点，对投诉集中的商品质量、售后服务等问题提前提示，确保消费纠纷在萌芽状态得到 妥善解决；要推进规范化建设，优化运行管理机制。严格按照消费维权服务站建设标准要求，进一步明 确工作职责、规范处置流程、加强人员配置，做到"有机构、有制度、有人员、有台账、有结果"，确保 消费者"找得到人、解决得了问题"，不断优化消费投诉处置的全流程管理模式，实现消费维权服务的标 准化、透明化和闭环化管理；要发挥行业自律作用，构建社会共治格局。行业协会要充分发挥桥梁纽带 作用，建立健全行业自律公约和服务标准，组建专业调解队伍，开展专业化纠纷调解，形成行政调解与 行业调解互补的多元化解机制，共同营造安全、便利、诚信的消费环境。（尚桐） 为切实提升消费维权服务效能，8月26日，运城市市场监管局党组书记、局长景莉莉带队前往盐湖区、 运城经济技术开发区，对12315消费维权服务站建设运行情况进行调研。市局党组成 ...

Summary of Key Points Core Viewpoint - The company has provided guarantees for its subsidiaries, which are essential for their operational financing and growth, while ensuring that these guarantees are within the approved limits and backed by counter-guarantees from the subsidiaries [1][2][3]. Group 1: Guarantee Overview - The company has provided a guarantee of RMB 107.80 million for its wholly-owned subsidiary, Tibet Nordicon Biopharmaceutical Sales Co., Ltd., and RMB 100 million for its controlling subsidiary, Tibet Nordicon Pharmaceutical Co., Ltd. [1][2] - The total actual guarantee balance provided by the company is RMB 218.80 million for the biopharmaceutical subsidiary and RMB 350 million for the pharmaceutical subsidiary as of the announcement date [1][2]. - Both subsidiaries have provided counter-guarantees to the company [1][2]. Group 2: Internal Decision-Making Process - The company held board meetings on March 13, 2025, and April 8, 2025, to approve the guarantee and credit limit proposals, allowing a total credit limit of up to RMB 1 billion for the year 2025 [2][3]. - The controlling subsidiary's credit limit is capped at RMB 800 million, with the company providing joint liability guarantees for all debts incurred within this limit [2][3]. Group 3: Financial Data of Subsidiaries - Tibet Nordicon Biopharmaceutical Sales Co., Ltd. has total assets of RMB 440.84 million, net assets of RMB 130.46 million, total liabilities of RMB 310.38 million, operating income of RMB 1.29 billion, and a net profit of RMB 67.12 million, with an asset-liability ratio of 70.41% [4]. - Tibet Nordicon Pharmaceutical Co., Ltd. has total assets of RMB 1.13 billion, net assets of RMB 672.72 million, total liabilities of RMB 452.93 million, operating income of RMB 1.37 billion, and a net profit of RMB 121.28 million, with an asset-liability ratio of 40.24% [5]. Group 4: Guarantee Agreement Details - The guarantee for Tibet Nordicon Biopharmaceutical Sales Co., Ltd. is with China Bank, with a limit of RMB 107.80 million, covering all principal, interest, penalties, and related costs for three years [5][6]. - The guarantee for Tibet Nordicon Pharmaceutical Co., Ltd. is with Citic Bank, with a limit of RMB 100 million, covering similar financial obligations for three years [5][6]. Group 5: Risk Management and Control - The company maintains effective control over the operational risks and decision-making of its subsidiaries, ensuring that the risks associated with the guarantees are manageable [6][7]. - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 800 million, with no overdue guarantees reported [7].

Group 1 - The Hong Kong pharmaceutical sector has seen significant growth, with the Hong Kong pharmaceutical ETF rising over 2%, and companies like 3SBio, BeiGene, and Innovent Biologics showing strong performance, attracting investor attention [1] - The domestic largest out-of-hospital pharmaceutical sales platform, Yaoshi Bang, has experienced a strong upward trend in its stock price, with a year-to-date increase of over 68%, and a total market capitalization exceeding HKD 5.6 billion [1] - Yaoshi Bang reported its first annual profit in 2024, with a net profit of HKD 157 million, a year-on-year increase of 20.1%, and significant growth in high-margin business segments [1] Group 2 - The company has shown strong cash flow performance, with operating cash flow increasing from HKD 98.2 million in 2022 to HKD 656 million in 2024 [1] - A share buyback plan of HKD 100 million was announced, with a total of 4.457 million shares repurchased for over HKD 33.99 million from May 7 to May 21 [1] - The largest shareholder and founder of Yaoshi Bang has not sold any shares since the company went public in 2023, indicating stable ownership structure [2] Group 3 - Company executives have actively increased their holdings, with the executive director purchasing 700,000 shares between April and May, reflecting confidence in the company's future [2] - The digital pharmaceutical market in which Yaoshi Bang operates has significant growth potential, with increasing digital healthcare penetration and demand from grassroots levels [2] - Despite a slight pullback, the company's stock price has maintained an upward trend for two consecutive weeks, supported by strong fundamentals and the share buyback plan [2]

Summary of Key Points Core Viewpoint - The company has provided a guarantee of RMB 41 million for its wholly-owned subsidiary, Tibet Nodi Kang Biomedical Sales Co., Ltd., with a total guarantee balance of RMB 191 million as of the announcement date [1][5]. Group 1: Guarantee Overview - The company has signed a guarantee contract with Bank of China, Shannan Branch, to provide a joint liability guarantee for the subsidiary's credit business, not exceeding RMB 41 million [5]. - The subsidiary has provided counter-guarantees to the company [2][9]. - There are no overdue guarantees reported [3]. Group 2: Internal Decision-Making Process - The company held board meetings on March 13, 2025, and April 8, 2025, to approve the guarantee and credit limit for the subsidiary, allowing a total credit limit of up to RMB 1 billion for the year 2025 [6]. - The approval process for the guarantee is within the authorized limits and complies with relevant regulations [6]. Group 3: Subsidiary Information - Tibet Nodi Kang Biomedical Sales Co., Ltd. was established on July 25, 2022, with a registered capital of RMB 28 million [7]. - The company holds 100% ownership of the subsidiary [8]. Group 4: Guarantee Agreement Details - The guarantee covers all debts under the main contract, including principal, interest, penalties, and other related costs [8][9]. - The guarantee period lasts for three years from the maturity of the main debt [9]. Group 5: Overall Guarantee Situation - The total external guarantees provided by the company and its subsidiaries amount to RMB 800 million, representing 20.24% of the latest audited net assets [10]. - The actual balance of guarantees is RMB 541 million, accounting for 13.69% of the latest audited net assets [10].